Report Scope & Overview:
The Toxoid Vaccine Market size was worth US$ 5.61 billion in 2022 and is estimated to reach US$ 8.22 billion by 2030, growing at a CAGR of 4.9% during the forecast period 2023-2030.
The rowing cases of tetanus and diphtheria are boosting the global toxoid vaccine market growth in the forecasted period. Various immunization campaigns by different government and non-government organizations also contribute to market growth. The global toxoid vaccines market growth is also driven by several factors, such as increasing government initiatives for vaccination programs and growing research & development activities for new vaccines. According to the WHO COVID-19 has created a huge gap in general immunizations globally. The toxoid market is moderately competitive owing to the key strategies performed by different key market players for holding most of the market share. The tetanus segment held the largest market share in 2022 and is expected to continue throughout the forecast period 2023-2030, owing to the increasing number of tetanus cases globally. Tetanus is an uncommon but very dangerous disease of every 9 people who get it, as many as 2 will die and requires treatment in a medical facility, often in a referral hospital. However, the toxoid vaccine market is hampered by several side effects associated with the toxoid vaccine, which lowers its preferability. The vaccine causes redness and pain at the site of injection, fever, fatigue, and muscle pains.
To Get More Information on Toxoid Vaccine Market - Request Sample Report
The Increasing Burden of Tetanus Infectious
Low Demands for These Vaccines in the Developed Regions
Growing Research and Development Activities for New Vaccines
The initiatives taken by the government to prevent the disease
Side-effects Associated with Toxoid Vaccine
Impact of Covid-19
The tetanus toxoid vaccine market is significantly impacted by COVID-19. According to the study published by the National Institutes of Health in January 2021, "Does tetanus vaccination contribute to reduced severity of the COVID-19 infection?" tetanus vaccination may help to reduce the severity of COVID19 infection, but more research is needed to confirm or refute the effectiveness of the tetanus toxoid vaccine against COVID-19. Additionally, according to the article published in the Frontier Journal in October 2021, by Jennifer Monereo-Sánchez, vaccination against diphtheria or tetanus is linked to less severe COVID-19 symptoms. By stimulating the immune system, these vaccinations may protect against severe COVID-19 symptoms. Ø During the outburst, the pandemic negatively impacted the global market because to prevent further COVID-19 infection spread, restrictions and regulations were imposed, making it difficult for people to perform immunizations which left a large pool of children unimmunized. For instance, according to the WHO, the third dose of diphtheria, tetanus toxoid, and pertussis-containing vaccine coverage in one-year-olds globally decreased from 86% in 2019 to 81% in 2021, which accounted for around 25 million children missing out on vaccination, 6 million more than in 2019 and the highest number since 2009. A 2020 study investigated the bacterial vaccines DTP and meningitis B and deduced that children’s likely protection against SARS-CoV-2 could be down to cross-reactivity prompted by these vaccinations.
Key Market Segmentation:
Diphtheria, Tetanus, and Pertussis (DtaP)
Diphtheria and Tetanus (DT)
Tetanus, Diphtheria, and Pertussis (Tdap)
Monovalent Tetanus Toxoid (TT)
Tetanus and Diphtheria (Td)
By End User
Hospitals and clinics
Need any customization research on Toxoid Vaccine Market - Enquiry Now
The presence of most of the key market players in the United States holding most of the global toxoid market through various market strategies such as collaborations, Disease launches, acquisitions, and others contribute to the growth of the North American toxoid vaccine market throughout the forecast period.
The increased immunization gap in Europe will lead to increased demand for vaccine deployment and refrigerated storage solutions in the upcoming years. For instance, according to WHO Regional Office for Europe, though with current immunization coverage rates, up to 1 million children born each year in the WHO European Region will not receive all of the recommended vaccinations in their lifetimes and thus will not receive the protection from the disease that is their fundamental right.
The Asia Pacific is a rapidly growing market for toxoid vaccines because of the raising number of tetanus, diphtheria, and pertussis cases in the region and government initiatives to produce awareness concerning immunization programs to eradicate epidemic diseases. Market developments by the key players from this region
The major key players are Sanofi S.A. ,Serum Institute of India Pvt. Ltd. , Panacea Biotec, Biological E Limited, GlaxoSmithKline, Merck & Co. Inc., Astellas Pharma Inc., Bharat Biotech, Dano Vaccines, Abbott. & Others
|Market Size in 2022||US$ 5.61 Billion|
|Market Size by 2030||US$ 8.22 Billion|
|CAGR||CAGR of 4.9 % From 2023 to 2030|
|Report Scope & Coverage||Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook|
|Key Segments||• By Disease (Tetanus, Diphtheria, Pertussis)
• By Composition (Diphtheria, Tetanus, and Pertussis (DtaP), Diphtheria and Tetanus (DT), Tetanus, Diphtheria, and Pertussis (Tdap), Monovalent Tetanus Toxoid (TT), Tetanus and Diphtheria (Td))
• By End User (Hospitals, Specialty, Governments Organization, Others)
|Regional Analysis/Coverage||North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America)|
|Company Profiles||Sanofi S.A. ,Serum Institute of India Pvt. Ltd. , Panacea Biotec, Biological E Limited, GlaxoSmithKline, Merck & Co. Inc., Astellas Pharma Inc., Bharat Biotech, Dano Vaccines, Abbott.|
|Key Drivers||• The Increasing Burden of Tetanus Infectious|
|Market Opportunity||• Growing Research and Development Activities for New Vaccines
• The initiatives taken by the government to prevent the disease
Ans: The Toxoid Vaccine market is growing at a CAGR of 4.9% Over the Forecast Period 2023-2030.
The tetanus toxoid vaccine market is significantly impacted by COVID-19.
Ans: The global toxoid Vaccine Market size is expected to reach at USD 8.22 Bn by 2030.
The Increasing Burden of Tetanus Infectious are the fuel growth factors of Toxoid vaccine market.
Table of Contents
1.1 Market Definition
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
4.1 COVID-19 Impact Analysis
4.2 Impact of the Ukraine- Russia War
4.3 Impact of Ongoing Recession
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Cardiac Implant Market Segmentation, by Disease Type
9. Cardiac Implant Market Segmentation, by Composition
9.1 Diphtheria, Tetanus, and Pertussis (DtaP)
9.2 Diphtheria and Tetanus (DT)
9.3 Tetanus, Diphtheria, and Pertussis (Tdap)
9.4 Monovalent Tetanus Toxoid (TT)
9.5 Tetanus and Diphtheria (Td)
10. Cardiac Implant Market Segmentation, by End User
10.2 Government Organization
11. Regional Analysis
11.2 North America
22.214.171.124 USA Cardiac Implant Market by Disease Type
126.96.36.199 USA Cardiac Implant Market by Composition
188.8.131.52 USA Cardiac Implant Market by End User
184.108.40.206 Canada Cardiac Implant Market by Disease Type
220.127.116.11 Canada Cardiac Implant Market by Composition
18.104.22.168 Canada Cardiac Implant Market by End User
22.214.171.124 Mexico Cardiac Implant Market by Disease Type
126.96.36.199 Mexico Cardiac Implant Market by Composition
188.8.131.52 Mexico Cardiac Implant Market by End User
184.108.40.206 Germany Cardiac Implant Market by Disease Type
220.127.116.11 Germany Cardiac Implant Market by Composition
18.104.22.168 Germany Cardiac Implant Market by End User
22.214.171.124 UK Cardiac Implant Market by Disease Type
126.96.36.199 UK Cardiac Implant Market by Composition
188.8.131.52 UK Cardiac Implant Market by End User
184.108.40.206 France Cardiac Implant Market by Disease Type
220.127.116.11 France Cardiac Implant Market by Composition
18.104.22.168 France Cardiac Implant Market by End User
22.214.171.124 Italy Cardiac Implant Market by Disease Type
126.96.36.199 Italy Cardiac Implant Market by Composition
188.8.131.52 Italy Cardiac Implant Market by End User
184.108.40.206 Spain Cardiac Implant Market by Disease Type
220.127.116.11 Spain Cardiac Implant Market by Composition
18.104.22.168 Spain Cardiac Implant Market by End User
11.3.6 The Netherlands
22.214.171.124 Netherlands Cardiac Implant Market by Disease Type
126.96.36.199 Netherlands Cardiac Implant Market by Composition
188.8.131.52 Netherlands Cardiac Implant Market by End User
11.3.7 Rest of Europe
184.108.40.206 Rest of Europe Cardiac Implant Market by Disease Type
220.127.116.11 Rest of Europe Cardiac Implant Market by Composition
18.104.22.168 Rest of Europe Cardiac Implant Market by End User
22.214.171.124 Japan Cardiac Implant Market by Disease Type
126.96.36.199 Japan Cardiac Implant Market by Composition
188.8.131.52 Japan Cardiac Implant Market by End User
11.4.2 South Korea
184.108.40.206 South Korea Cardiac Implant Market by Disease Type
220.127.116.11 South Korea Cardiac Implant Market by Composition
18.104.22.168 South Korea Cardiac Implant Market by End User
22.214.171.124 China Cardiac Implant Market by Disease Type
126.96.36.199 China Cardiac Implant Market by Composition
188.8.131.52 China Cardiac Implant Market by End User
184.108.40.206 India Cardiac Implant Market by Disease Type
220.127.116.11 India Cardiac Implant Market by Composition
18.104.22.168 India Cardiac Implant Market by End User
22.214.171.124 Australia Cardiac Implant Market by Disease Type
126.96.36.199 Australia Cardiac Implant Market by Composition
188.8.131.52 Australia Cardiac Implant Market by End User
11.4.6 Rest of Asia-Pacific
184.108.40.206 APAC Cardiac Implant Market by Disease Type
220.127.116.11 APAC Cardiac Implant Market by Composition
18.104.22.168 APAC Cardiac Implant Market by End User
11.3 The Middle East & Africa
22.214.171.124 Israel Cardiac Implant Market by Disease Type
126.96.36.199 Israel Cardiac Implant Market by Composition
188.8.131.52Israel Cardiac Implant Market by End User
184.108.40.206 UAE Cardiac Implant Market by Disease Type
220.127.116.11 UAE Cardiac Implant Market by Composition
18.104.22.168 UAE Cardiac Implant Market by End User
11.3.3 South Africa
22.214.171.124 South Africa Cardiac Implant Market by Disease Type
126.96.36.199 South Africa Cardiac Implant Market by Composition
188.8.131.52 South Africa Cardiac Implant Market by End User
11.3.4 Rest of Middle East & Africa
184.108.40.206 Rest of Middle East & Asia Cardiac Implant Market by Disease Type
220.127.116.11 Rest of Middle East & Asia Cardiac Implant Market by Composition
18.104.22.168 Rest of Middle East & Asia Cardiac Implant Market by End User
11.6 Latin America
22.214.171.124 Brazil Cardiac Implant Market by Disease Type
126.96.36.199 Brazil Cardiac Implant Market by Composition
188.8.131.52 Brazil Cardiac Implant Market by End User
184.108.40.206 Argentina Cardiac Implant Market by Disease Type
220.127.116.11 Argentina Cardiac Implant Market by Composition
18.104.22.168 Argentina Cardiac Implant Market by End User
11.6.3 Rest of Latin America
22.214.171.124 Rest of Latin America Cardiac Implant Market by Disease Type
126.96.36.199 Rest of Latin America Cardiac Implant Market by Composition
188.8.131.52 Rest of Latin America Cardiac Implant Market by End User
12. Company Profile
12.1 Sanofi S.A
12.1.1 Market Overview
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 Serum Institute of India Pvt. Ltd,
12.2.1 Market Overview
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3 Panacea Biotec,
12.3.1 Market Overview
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 Biological E Limited,
12.4.1 Market Overview
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.3.1 Market Overview
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.6 Inc Medtronic Private Limited
12.6.1 Market Overview
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 Merck & Co. Inc,
12.7.1 Market Overview
12.7.4 SWOT Analysis
12.7.5 The SNS View
12.8 Astellas Pharma Inc
12.8.1 Market Overview
12.8.4 SWOT Analysis
12.8.5 The SNS View
12.9 Bharat Biotech
12.9.1 Market Overview
12.9.4 SWOT Analysis
12.9.5 The SNS View
12.10.1 Market Overview
12.10.4 SWOT Analysis
12.10.5 The SNS View
12.11 Dano Vaccines
12.11.1 Market Overview
12.11.4 SWOT Analysis
12.11.5 The SNS View
13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share Analysis
13.3 Recent Developments
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
In 2022, The Alopecia Treatment Market size amounted to USD 8.0 Billion & is estimated to reach USD 16.12 Billion by 2030 and increase at a compound annual growth rate of 9.2% between 2023 and 2030.
The Dialysis Market was valued at USD 93 Bn in 2022 and is expected to reach USD 135 Bn by 2030 and grow at a CAGR of 4.8% over the forecast period of 2023-2030.
The Bone Graft Market size was valued at US$ 4.46 Billion in 2022 and is projected to reach US$ 6.69 Billion by 2030, with a growing CAGR of 5.2% over the forecast period 2023-2030.
The Postpartum Products Market size was estimated USD 2.38 billion in 2022 and is expected to reach USD 3.97 billion by 2030 at a CAGR of 6.6% during the forecast period of 2023-2030.
The mHealth Market size is expected to reach USD 127 Bn by 2030, the base value of the market was valued at USD 56.8 Bn in 2022. The CAGR growth rate was recorded 10.6% over the forecast period of 2023-2030.
The Microplate Reader Market size was estimated USD 453.7 million in 2022 and is expected to reach USD 815.2 million by 2030 at a CAGR of 7.6% during the forecast period of 2023-2030.
Hi! Click one of our member below to chat on Phone